Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vigil + Nivolumab in Advanced NSCLC
NCT02639234Phase 2Withdrawn
- Sponsor
- Gradalis, Inc.
- Start
- Mar 2016
- Primary completion
- Mar 2017
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA), Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of gemogenovatucel-T in non-small cell lung cancer (NSCLC), sponsored by Gradalis, Inc.. Planned start Mar 2016; status: withdrawn.
02
Drugs
gemogenovatucel-T
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02639234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02639234.